Format

Send to

Choose Destination
Bioorg Med Chem Lett. 2010 Jul 1;20(13):3925-9. doi: 10.1016/j.bmcl.2010.05.013. Epub 2010 May 12.

Reducing ion channel activity in a series of 4-heterocyclic arylamide FMS inhibitors.

Author information

1
Johnson & Johnson Pharmaceutical Research & Development, Spring House, PA 19477, USA. kwilso10@its.jnj.com

Abstract

During efforts to improve the bioavailability of FMS kinase inhibitors 1 and 2, a series of saturated and aromatic 4-heterocycles of reduced basicity were prepared and evaluated in an attempt to also improve the cardiovascular safety profile over lead arylamide 1, which possessed ion channel activity. The resultant compounds retained excellent potency and exhibited diminished ion channel activity.

PMID:
20570147
DOI:
10.1016/j.bmcl.2010.05.013
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center